We are live on ! Find out more

Alector

ALEC

Market cap $213M

1.91 USD

+0.06

3.24%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

1.92

+0.01

0.52%

1 day

3.24%

5 days

-11.16%

1 month

-13.57%

3 months

9.14%

6 months

-6.83%

Year to date

24.84%

1 year

-38.98%

5 years

-92.59%

10 years

-89.39%

About: Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Employees: 103

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 66.7%

Negative 33.3%

Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript

Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript

Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.

Alector to Participate in Upcoming Healthcare Conferences

Zacks Investment Research

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)).

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Alector and GSK partnership to end after dementia, Alzheimer's drug failures

Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both ‌the drug candidates suffered clinical setbacks.

Alector and GSK partnership to end after dementia, Alzheimer's drug failures

Zacks Investment Research

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago.

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Zacks Investment Research

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease (AD) will be discontinued.

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

See News Rankings

Price charts implemented using Lightweight Charts™